Journal of Clinical Endocrinology & Metabolism, Vol 81, 333-339, Copyright © 1996 by Endocrine Society

ARTICLES

Current trends in the management of well differentiated papillary thyroid carcinoma

BL Solomon, L Wartofsky and KD Burman
Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, D.C. 20307-5001, USA.

Clinical members of the American Thyroid Association were surveyed in regard to their diagnostic assessment, treatment, and long term assessment of differentiated papillary thyroid carcinoma. For a 39-yr- old female with a 2-cm solitary nodule and no history of radiation (index patient), respondents were asked to provide their preferences for diagnostic evaluation, treatment assuming a papillary carcinoma was focal, and follow-up. Of 408 surveys mailed, 233 (57.1%) were analyzed. Diagnostic studies included thyroid scan (56%), fine needle aspiration (96%), total serum T4 (49%), and third generation TSH (56%). Treatment included surgery (99%), with 86% preferring near-total/total thyroidectomy. After surgery, 61% recommended 131I ablation; long term therapy using L-T4 alone was recommended by 97%, with most preferring suppression to a target TSH level of less than 0.01 microIU/mL (22%), 0.01-0.05 (38%), or 0.06-0.50 (32%). For variations from the index patient, respondents' treatment were not different for a history of radiation, age of either 16 or 60 yr, nodule size of 1.5 cm, male sex, the presence of less than 1-cm multiple foci in the contralateral lobe, or capsular invasion of the nodule. Treatment and follow-up did change if there was blood vessel invasion or distant metastasis. In summary, our survey indicated consensus on diagnostic assessment of the index patient by fine needle aspiration and management by surgery and 131I therapy. However, management varied widely for the ablative dose of 131I, the target TSH level after ablation, and the frequency and type of follow up.

This article has been cited by other articles:

				E. Mazzaferri A Randomized Trial of Remnant Ablation--In Search of an Impossible Dream? J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3662 - 3664. [Full Text] [PDF]

				P. Chinnappa, L. Taguba, R. Arciaga, C. Faiman, A. Siperstein, A. E. Mehta, S. K. Reddy, C. Nasr, and M. K. Gupta Detection of Thyrotropin-Receptor Messenger Ribonucleic Acid (mRNA) and Thyroglobulin mRNA Transcripts in Peripheral Blood of Patients with Thyroid Disease: Sensitive and Specific Markers for Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3705 - 3709. [Abstract] [Full Text] [PDF]

				J. C. Sisson, B. L. Shulkin, and S. Lawson Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of 131I J. Nucl. Med., June 1, 2003; 44(6): 898 - 903. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, F. Pacini, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1433 - 1441. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, L. Pagano, M. Klain, G. Scherillo, M. Salvatore, G. Fenzi, G. Lombardi, and S. Fazio Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 211 - 214. [Abstract] [Full Text] [PDF]

				M. Paessler, F. H. C. Kreisel, V. A. LiVolsi, L. A. Akslen, and Z. W. Baloch Can We Rely on Pathologic Parameters to Define Conservative Treatment of Papillary Thyroid Carcinoma? International Journal of Surgical Pathology, October 1, 2002; 10(4): 267 - 272. [Abstract] [PDF]

				M. K. Gupta, L. Taguba, R. Arciaga, A. Siperstein, C. Faiman, A. Mehta, and S. S. K. Reddy Detection of Circulating Thyroid Cancer Cells by Reverse Transcription-PCR for Thyroid-stimulating Hormone Receptor and Thyroglobulin: The Importance of Primer Selection Clin. Chem., October 1, 2002; 48(10): 1862 - 1865. [Full Text] [PDF]

				N. Magne, J. Magne, J. Bracco, and F. Bussiere Disposition of Radioiodine 131I Therapy for Thyroid Carcinoma in a Patient with Severely Impaired Renal Function on Chronic Dialysis: a Case Report Jpn. J. Clin. Oncol., June 1, 2002; 32(6): 202 - 205. [Abstract] [Full Text] [PDF]

				L. Wartofsky Using Baseline and Recombinant Human TSH-Stimulated Tg Measurements to Manage Thyroid Cancer without Diagnostic 131I Scanning J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1486 - 1489. [Full Text] [PDF]

				M. Kitazono, R. Robey, Z. Zhan, N. J. Sarlis, M. C. Skarulis, T. Aikou, S. Bates, and T. Fojo Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I- Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3430 - 3435. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				M. Kitazono, Y. Chuman, T. Aikou, and T. Fojo Construction of Gene Therapy Vectors Targeting Thyroid Cells: Enhancement of Activity and Specificity with Histone Deacetylase Inhibitors and Agents Modulating the Cyclic Adenosine 3',5'-Monophosphate Pathway and Demonstration of Activity in Follicular and Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 834 - 840. [Abstract] [Full Text]

				F. N. Bennedbæk and L. Hegedüs Management of the Solitary Thyroid Nodule: Results of a North American Survey J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2493 - 2498. [Abstract] [Full Text]

				R. E. Gardner, R. M. Tuttle, K. D. Burman, S. Haddady, C. Truman, Y. H. Sparling, L. Wartofsky, R. B. Sessions, and M. D. Ringel Prognostic Importance of Vascular Invasion in Papillary Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 2000; 126(3): 309 - 312. [Abstract] [Full Text] [PDF]

				M. Derwahl, M. Broecker, and Z. Kraiem Thyrotropin May Not Be the Dominant Growth Factor in Benign and Malignant Thyroid Tumors J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 829 - 834. [Full Text]

				L. Wartofsky Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4195 - 4199. [Full Text]

				A. Dwarakanathan Suppressive Therapy for Thyroid Nodules Arch Intern Med, July 13, 1998; 158(13): 1470 - 1470. [Full Text]

				M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]

				C. H. Emerson and R. Colzani Epithelial Cell Thyroid Cancer and Thyroid Stimulating Hormone--When Less is More J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 9 - 10. [Full Text] [PDF]